The UK and US have announced a important bilateral deal that will maintain zero tariffs on UK medicine shipments being sold in the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to raise funding on medicines through the National Health Service (NHS). This commitment guarantees that import taxes on these vital goods will be held at nothing for a duration of 36 months.
This deal comes after previous warnings to significantly raise import taxes on patented pharmaceutical imports, with potential rates mentioned as high as one hundred percent.
"This arrangement with the UK reinforces the global environment for cutting-edge drugs and establishes much-needed balance to transatlantic medicine commerce," a release noted.
Economic Significance
Drugs represent one of the UK's most significant export categories to the US, which is clearly the largest market for large British pharmaceutical firms.
Trade data indicate that in the one-year period to the end of last September, the UK shipped medicines totaling billions to the US. This figure represented a significant portion of British export trade in that period.
"This agreement secures employment, boosts capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," the Business and Trade Secretary stated.
Specific British Pledges
The pact entails several notable pledges from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a target to double total NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, repayments topped 20%.
Broader Context
This agreement follows a ongoing row between the drug companies and the UK government over medicine costs and approval rates.
These tensions were exacerbated by assertions that US patients were charged significantly more for the equivalent treatments than patients in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been announced toward American operations.
A senior figure acknowledged that the NHS must spend more on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
